News Releases June 13, 2022 Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention
News Releases May 26, 2022 Anthos Therapeutics Appoints Drew Young as Chief Commercial Officer and Head of Patient Experience
News Releases May 05, 2022 Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
News Releases March 07, 2022 Atrial Fibrillation Clinical Trial with Novel Dual Activity Factor XI Agent Completes Enrollment
News Releases July 19, 2021 ABELACIMAB SIGNIFICANTLY OUTPERFORMS STANDARD OF CARE IN PHASE 2 EFFICACY RESEARCH
News Releases July 06, 2021 Factor XI Inhibition: The Holy Grail of Hemostasis‐ Sparing Anticoagulation
News Releases July 19, 2021 Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine
News Releases July 06, 2021 Blackstone Life Sciences and Novartis Create Anthos Therapeutics to Develop Innovative Targeted Medicines for Cardiovascular Disease